Learn Mode

SYK - Stryker Corp

179

$327.44

-$5.24 (-1.575%)

At market close

$327.01

-$0.43 (-0.131%)

After Hours 3/27/26, 11:34 PM

3.86/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

SYK

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$125.31B

Industry

Health Care

EPS (TTM)

$8.40

P/E (TTM)

38.60

Div & Yield

$3.52 (1.08%)

FCF Payout Ratio

31.45%

P/S (TTM)

4.99

P/B

5.59

Diluted Shares

386.50M

Ex-Dividend

2026-03-31

Next Earnings

04-29

Forward P/E

21.60

Payout Ratio

41.50%

P/FCF (TTM)

29.26

FCF Yield

3.42%

Earnings Yield

2.59%

52 Week Range

Score Card

Explore Scores Tab

3.86

Good

Stryker Corp has grown revenue at 11.16% over the past year, which is strong growth. Also, it has seen its operating income increase by 12.78% over the past year, which suggests its operations are becoming much more profitable.

Valuation Model

Key Score

4.00

Good

Management

3.00

Average

Growth

2.00

Bad

Profitability

2.00

Bad

Fin. Health

1.00

Very Bad

Dividends

3.00

Average

Analyst

3.00

Average

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

13 new filings were in the last 7 days

Filter Form Types

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-27 13:20:03

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-24 17:17:58

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-24 17:14:47

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-24 17:11:39

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-24 17:07:46

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-24 17:04:24

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-24 16:59:23

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-24 16:55:26

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-24 16:52:12

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-24 16:48:36

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-03-23 13:15:04

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-03-23 13:05:14

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-02-21

High:

$492.45

50.4%

Avg:

$433.16

32.3%

Low:

$321.07

-1.9%

(% change is relative to the current stock price: $327.44)

Analyst Recommendations

Go to Analyst Tab

4.08

Good

32%

Strong Buy (12)

43%

Buy (16)

24%

Hold (9)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://www.stryker.com/
Address
1941 Stryker Way, Portage MICHIGAN, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=310764

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. The company is headquartered in Portage, Michigan and currently employs 56,000 full-time employees. The firm offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics products primarily include implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. The firm also offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs.

IPO Date

1980-03-17

Industry

Health Care

Total Employees

56,000

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Health Care Equipment & Supplies

GICS Sub

Health Care Equipment

GICS Sector

Health Care

GICS Group

Health Care Equipment & Services